Alzheon updates on precision medicine approach to treating AD

The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London.

The company is conducting a Phase III program investigating ALZ-801, an anti-amyloid drug candidate, as a potential treatment for Alzheimer’s disease.

ALZ-801 is an optimized prodrug of tramiprosate. A prodrug is a compound that is metabolized into a pharmacologically active drug after it has been administered.

Read the full article here.
2017-08-17T10:12:54+00:00July 17th, 2017|Tags: |